Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes

被引:70
作者
Marculescu, R
Endler, G
Schillinger, M
Iordanova, N
Exner, M
Hayden, E
Huber, K
Wagner, O
Mannhalter, C
机构
[1] Univ Vienna, AKH Wien, Sch Med, Dept Lab Med, A-1090 Vienna, Austria
[2] Univ Vienna, Sch Med, Div Angiol, Dept Internal Med 2, A-1090 Vienna, Austria
[3] Univ Vienna, Sch Med, Div Cardiol, Dept Internal Med 2, A-1090 Vienna, Austria
[4] Univ Vienna, Sch Business Econ & Comp Sci, Dept Business Adm, Vienna, Austria
关键词
D O I
10.2337/diabetes.51.12.3582
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, inflammation has received considerable attention in the pathogenesis of both type 2 diabetes and atherosclerosis. The interleukin-1 receptor antagonist (IL-1ra) is a major modulator of the interleukin-1 proinflammatory pathway. We studied the relationship between a variable number tandem repeat (VNTR) polymorphism in intron 2 of the IL-1ra gene (IL1RN) and coronary artery disease (CAD) in patients with and without type 2 diabetes, following 787 consecutive patients admitted for suspected CAD. According to the current criteria of the American Diabetes Association, 250 patients had type 2 diabetes. In this group of patients, allele 2 carriers (n = 108) had an increased prevalence of CAD compared with noncarriers (85.2 vs. 73.2%), a difference that remained significant in a multivariate logistic regression model (odds ratio 2.2, 95% CI 1.1-4.3, P = 0.02). No association of CAD with allele 2 carrier status was present among nondiabetic patients (n = 537). Enzyme-linked immunosorbent assays showed decreased baseline plasma levels of IL-1ra in patients with type 2 diabetes, which may in part explain the role of the IL1RN VNTR in these patients.
引用
收藏
页码:3582 / 3585
页数:4
相关论文
共 15 条
[1]  
Blakemore AIF, 1996, HUM GENET, V97, P369, DOI 10.1007/BF02185776
[2]   INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AS A DISEASE SEVERITY FACTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BLAKEMORE, AIF ;
TARLOW, JK ;
CORK, MJ ;
GORDON, C ;
EMERY, P ;
DUFF, GW .
ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1380-1385
[3]   Relationship between fasting plasma glucose and glycosylated hemoglobin - Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria [J].
Davidson, MB ;
Schriger, DL ;
Peters, AL ;
Lorber, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (13) :1203-1210
[4]   Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications -: The effect of α-tocopherol supplementation [J].
Devaraj, S ;
Jialal, I .
CIRCULATION, 2000, 102 (02) :191-196
[5]   Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes - The insulin resistance atherosclerosis study [J].
Festa, A ;
D'Agostino, R ;
Tracy, RP ;
Haffner, SM .
DIABETES, 2002, 51 (04) :1131-1137
[6]   Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease [J].
Francis, SE ;
Camp, NJ ;
Dewberry, RM ;
Gunn, J ;
Syrris, P ;
Carter, ND ;
Jeffery, S ;
Kaski, JC ;
Cumberland, DC ;
Duff, GW ;
Crossman, DC .
CIRCULATION, 1999, 99 (07) :861-866
[7]   C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study [J].
Freeman, DJ ;
Norrie, J ;
Caslake, MJ ;
Gaw, A ;
Ford, I ;
Lowe, GDO ;
O'Reilly, DS ;
Packard, CJ ;
Sattar, N .
DIABETES, 2002, 51 (05) :1596-1600
[8]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]  
Hurme M, 1998, EUR J IMMUNOL, V28, P2598, DOI 10.1002/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.3.CO
[10]  
2-B